ELI LILLY & Co
LLYNYSELatest results at a glance
Insights from the latest company results and reports · filed 5 Aug 2026
Q2 2026 Revenue and EPS Growth
Q2 2026 revenue increased 48% to $23.0 billion, driven primarily by Mounjaro and Zepbound volume. Q2 2026 EPS increased 26% to $7.94 on a reported basis and 33% to $8.38 on a non-GAAP basis, including $3.03 of acquired IPR&D charges.
Full-Year 2026 Guidance Raised
The company increased 2026 full-year revenue guidance to a range of $85.0 billion to $87.0 billion. Underlying non-GAAP EPS guidance was raised by $2.78 at the midpoint, resulting in an updated range of $35.50 to $36.50 after accounting for $3.03 in acquired IPR&D charges.
Gross Margin Expansion
Gross margin increased 50% to $19.7 billion in Q2 2026, with gross margin as a percent of revenue rising to 85.8%, an increase of 1.5 percentage points versus the same quarter last year. On a non-GAAP basis, gross margin increased 50% to $19.8 billion, with the margin percentage rising to 86.3%.
Earnings Consensus Exceedance
Reported EPS of $8.38 per share for the quarter ended 2026-06-30 exceeded the same-quarter consensus EPS of $6.58 per share.
Company research evidence
Checked financial measurements with the values, reporting periods and measurement basis shown together. This evidence is available independently of the AI report.
Loading evidence…
Deep Dive Research
Source-linked company research for LLY
Revenue segmentation
Loading segment disclosures…